Unlike currently approved weight loss medications, retatrutide works as a triple agonist, meaning it targets three different hormone receptors: GIP, GLP-1, and glucagon receptors
Triple-Hormone-Receptor Agonist Retatrutide for Obesity A Phase 2 Trial
For the future, scientists are investigating how it could address metabolic disorders other than obesity, including non-alcoholic fatty liver disease and insulin resistance
Independent Wellness is built around provider-led care rather than low-touch prescription fulfillment
Retatrutide, semaglutide, and tirzepatide all curb appetite, but they differ in how many hormone pathways they target
That was the part that sold me on this compound versus other options I had researched